epigenetic therapy for cancer

Epigenetic Therapy for Cancer: Unlocking New Frontiers in Treatment

epigenetic therapy for cancer has emerged as a groundbreaking approach that goes beyond traditional treatments like chemotherapy and radiation. Unlike conventional methods that directly target the DNA sequence, epigenetic therapy focuses on modifying the chemical tags and mechanisms that regulate gene expression without changing the underlying DNA code. This innovative strategy holds immense promise for combating various types of cancers by reactivating silenced tumor suppressor genes or shutting down oncogenes through reversible modifications.

Understanding the Basics of Epigenetics in Cancer

Before diving into epigenetic therapy for cancer, it’s important to grasp what epigenetics entails. At its core, epigenetics refers to the study of changes in gene activity that do not involve alterations in the DNA sequence itself. Instead, these changes occur through mechanisms such as DNA methylation, histone modification, and non-coding RNA activity. These epigenetic marks influence whether genes are turned on or off, thus controlling cellular functions and fate.

In cancer, the epigenetic landscape is often disrupted, leading to abnormal gene expression profiles. For instance, tumor suppressor genes may become silenced due to hypermethylation of their promoters, while oncogenes could be aberrantly activated. These epigenetic abnormalities contribute to tumor initiation, progression, metastasis, and drug resistance.

Key Epigenetic Mechanisms Involved in Cancer

Understanding the major epigenetic mechanisms is crucial to appreciate how epigenetic therapy works:

- **DNA Methylation:** The addition of methyl groups to cytosine bases in DNA, especially at CpG islands near gene promoters, often leads to gene silencing.
- **Histone Modifications:** Histones are proteins around which DNA wraps. Chemical changes like acetylation or methylation on histones can either open up the chromatin for gene expression or compact it to repress genes.
- **Non-Coding RNAs:** These RNA molecules regulate gene expression post-transcriptionally and can impact cancer-related gene networks.

How Epigenetic Therapy for Cancer Works

The essence of epigenetic therapy is to reverse aberrant epigenetic changes that drive cancer progression. This is typically achieved through drugs known as epigenetic modifiers or epidrugs, which target the enzymes responsible for maintaining these epigenetic marks.

Types of Epigenetic Therapies

Two main classes of epigenetic drugs have gained prominence:

- **DNA Methyltransferase Inhibitors (DNMTis):** These drugs inhibit DNA methyltransferases, enzymes that add methyl groups to DNA. By blocking DNA methylation, DNMTis can reactivate silenced tumor suppressor genes. Examples include azacitidine and decitabine, which have been approved for treating certain blood cancers like myelodysplastic syndromes and acute myeloid leukemia.

- **Histone Deacetylase Inhibitors (HDACis):** HDAC inhibitors prevent the removal of acetyl groups from histones, promoting a more open chromatin structure and enhancing gene expression. Vorinostat and romidepsin are among the HDAC inhibitors approved for cutaneous T-cell lymphoma.

Beyond these, ongoing research is exploring inhibitors targeting histone methyltransferases, demethylases, and other epigenetic regulators, broadening the therapeutic arsenal.

Combination Therapies and Personalized Medicine

One exciting avenue in epigenetic therapy for cancer is combining epidrugs with other treatments such as immunotherapy, chemotherapy, or targeted therapy. For example, epigenetic drugs can sensitize tumors to immune checkpoint inhibitors by increasing the expression of antigens or immune-related genes. This synergy has opened new doors in managing resistant or advanced cancers.

Furthermore, personalized medicine approaches are becoming increasingly important. Since epigenetic changes vary between individuals and cancer types, tailoring epigenetic therapy based on a patient’s specific epigenetic profile could improve treatment efficacy and reduce side effects.

Advantages and Challenges of Epigenetic Therapy

Why Epigenetic Therapy Holds Promise

Epigenetic therapy offers several unique benefits that distinguish it from conventional cancer treatments:

- **Reversibility:** Unlike genetic mutations, epigenetic modifications are reversible, allowing therapies to restore normal gene function.
- **Selective Targeting:** Epidrugs can selectively modulate gene expression patterns, potentially minimizing damage to healthy cells.
- **Overcoming Drug Resistance:** By reprogramming resistant cancer cells, epigenetic therapy can enhance the effectiveness of other therapies.
- **Wide Applicability:** Since epigenetic dysregulation is common across many cancer types, these therapies have broad potential.

Current Limitations and Areas Needing Improvement

Despite its potential, epigenetic therapy for cancer faces several hurdles:

- **Limited Specificity:** Some epidrugs affect multiple genes, leading to unintended consequences and toxicity.
- **Transient Effects:** Epigenetic changes induced by therapy may not be permanent, necessitating ongoing treatment.
- **Biomarker Identification:** Reliable biomarkers are needed to predict which patients will benefit most and to monitor response.
- **Complexity of Epigenetic Networks:** The epigenome is highly dynamic and interconnected, making it challenging to target without off-target effects.

Researchers are actively addressing these challenges by developing more selective inhibitors, novel delivery systems, and better patient stratification methods.

Real-World Impact: Success Stories and Ongoing Research

Epigenetic therapy has already made a tangible difference in clinical oncology. The FDA approval of

DNMT inhibitors and HDAC inhibitors for hematological malignancies marks a significant milestone. These drugs have improved survival rates and quality of life for patients with otherwise difficult-to-treat cancers.

Ongoing clinical trials are expanding the scope to solid tumors such as lung, breast, and prostate cancers, where epigenetic dysregulation also plays a vital role. The integration of epigenetic therapy with immunotherapy is particularly promising, as it may overcome immune evasion tactics employed by tumors.

Moreover, advances in epigenomic mapping and single-cell sequencing are deepening our understanding of cancer epigenetics, paving the way for next-generation therapies that are more effective and safer.

Looking Ahead: The Future of Epigenetic Therapy for Cancer

The future of epigenetic therapy for cancer is bright, with continuous innovations transforming the landscape. Precision epigenetics, which tailors treatments based on individual epigenomic profiles, will likely become the norm. Additionally, combining epigenetic drugs with emerging technologies such as CRISPR-based epigenome editing holds exciting potential to target cancer cells with unprecedented precision.

Patients and clinicians alike can be hopeful that as our knowledge of the epigenome grows, so will the effectiveness of these therapies, offering new hope for cancers that have resisted traditional treatments.

By embracing the complexity and reversibility of epigenetic mechanisms, cancer therapy is entering a new era—one where rewriting the epigenetic code could become a standard weapon in the fight against this formidable disease.

Frequently Asked Questions

What is epigenetic therapy for cancer?

Epigenetic therapy for cancer involves using drugs or other interventions to reverse abnormal epigenetic modifications, such as DNA methylation or histone modification, that contribute to cancer development and progression.

How do epigenetic drugs work in cancer treatment?

Epigenetic drugs, like DNA methyltransferase inhibitors and histone deacetylase inhibitors, work by reactivating tumor suppressor genes and altering gene expression patterns to inhibit cancer cell growth and induce apoptosis.

Which types of cancer are most commonly treated with epigenetic therapy?

Epigenetic therapy has shown effectiveness primarily in hematologic cancers such as myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and certain lymphomas, with ongoing research exploring its use in solid tumors.

What are the main challenges of epigenetic therapy in cancer?

Challenges include drug resistance, limited specificity leading to off-target effects, tumor heterogeneity, and the complexity of epigenetic regulation, which can affect therapeutic outcomes and patient response.

Are there any FDA-approved epigenetic therapies for cancer?

Yes, several epigenetic therapies like azacitidine and decitabine (DNA methyltransferase inhibitors) and vorinostat and romidepsin (histone deacetylase inhibitors) are FDA-approved for treating certain blood cancers.

Additional Resources

Epigenetic Therapy for Cancer: A Revolutionary Approach to Oncology Treatment

epigenetic therapy for cancer represents a transformative frontier in oncology, offering a novel avenue to combat malignancies by targeting the reversible modifications that regulate gene expression without altering the underlying DNA sequence. Unlike traditional therapies that focus on genetic mutations or directly attacking cancer cells, epigenetic therapy aims to reprogram the aberrant gene expression profiles characteristic of cancer cells. This therapeutic strategy holds the promise of precision medicine, potentially improving outcomes for patients with various types of cancer resistant to conventional treatments.

Understanding Epigenetic Therapy in Cancer Treatment

Epigenetics refers to the study of heritable changes in gene function that occur without changes in the DNA sequence. These alterations include DNA methylation, histone modification, and non-coding RNA-associated gene silencing, all of which play crucial roles in regulating gene expression. In cancer, epigenetic dysregulation often leads to the silencing of tumor suppressor genes or activation of oncogenes, contributing to tumor initiation, progression, and metastasis.

Epigenetic therapy for cancer primarily involves the use of agents that can reverse such epigenetic modifications. Two main classes of drugs have emerged as frontrunners: DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis). These agents aim to restore normal gene expression patterns by demethylating DNA or modifying histones, thereby reactivating suppressed genes involved in cell cycle control, apoptosis, and DNA repair.

Key Mechanisms Targeted by Epigenetic Therapy

- **DNA Methylation:** The addition of methyl groups to the cytosine residues in CpG islands often leads to gene silencing. DNMT inhibitors, such as azacitidine and decitabine, prevent this methylation, allowing re-expression of tumor suppressor genes.
- **Histone Modification:** Histone acetylation and deacetylation influence chromatin structure and gene accessibility. HDAC inhibitors like vorinostat and romidepsin promote a more relaxed chromatin state, facilitating transcriptional activation of critical genes.
- **Non-coding RNAs:** Though still emerging in clinical application, modulation of microRNAs and other non-coding RNAs represents another dimension of epigenetic therapy.

Clinical Applications of Epigenetic Therapy for Cancer

Epigenetic therapy has already made significant inroads in treating hematologic malignancies. Azacitidine and decitabine are FDA-approved for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), showing improved survival rates and quality of life for patients who often have limited treatment options. The success in blood cancers has spurred research into solid tumors, albeit with more complex challenges.

Success in Hematologic Malignancies

Clinical trials have demonstrated that DNMT inhibitors can induce remission in subsets of MDS and AML patients by reversing aberrant DNA methylation patterns. For instance, a landmark study showed that azacitidine treatment resulted in a median overall survival of 24.5 months compared to 15 months in a control group receiving conventional care. These results underscore the potential of epigenetic therapy to offer durable responses with manageable toxicity profiles.

Challenges in Solid Tumors

The application of epigenetic therapy to solid tumors such as lung, breast, and prostate cancers has been more challenging. Tumor heterogeneity, epigenetic complexity, and the tumor microenvironment contribute to variable responses. Nevertheless, combinations of epigenetic drugs with chemotherapy, immunotherapy, or targeted therapies are under active investigation. Early-phase trials combining HDAC inhibitors with immune checkpoint inhibitors have shown promise in overcoming resistance mechanisms.

Advantages and Limitations of Epigenetic Therapy

The reversible nature of epigenetic modifications offers a unique therapeutic advantage over genetic mutations, which are permanent. Epigenetic drugs can potentially "reset" cancer cells to a more normal phenotype or sensitize them to other treatments. Moreover, because epigenetic changes occur early in tumor development, these therapies could be effective in preventing progression or

relapse.

However, epigenetic therapy is not without drawbacks:

- **Non-specificity:** Epigenetic drugs may affect normal cells, leading to off-target effects and toxicities such as myelosuppression and gastrointestinal symptoms.
- **Transient Effects:** The epigenetic changes induced by therapy can be reversible, necessitating continuous treatment or combination strategies to maintain efficacy.
- **Biomarker Identification:** Reliable biomarkers to predict response are still under development, complicating patient selection and personalized treatment planning.

Emerging Strategies to Enhance Efficacy

To overcome these limitations, researchers are exploring more selective epigenetic modulators and combination regimens. For example, targeting specific histone methyltransferases or demethylases that are aberrantly expressed in certain cancers could minimize side effects. Integration of epigenetic therapy with immunotherapies seeks to modulate the tumor immune microenvironment, potentially enhancing anti-tumor immune responses.

Future Perspectives in Epigenetic Cancer Therapy

The landscape of epigenetic therapy for cancer is rapidly evolving. Advances in next-generation sequencing and epigenomic profiling have deepened understanding of the epigenetic alterations driving different cancer subtypes. This knowledge fuels the development of precision epigenetic therapies tailored to individual tumor profiles.

Moreover, liquid biopsies that detect circulating tumor DNA methylation patterns may enable real-time monitoring of treatment response and early detection of relapse. Such tools could facilitate adaptive therapy approaches, optimizing dosing and timing to maximize clinical benefit.

The integration of artificial intelligence and machine learning is also poised to accelerate the discovery of novel epigenetic drug targets and predict patient outcomes more accurately. As multidisciplinary research efforts continue, epigenetic therapy stands to become a cornerstone of personalized oncology, complementing existing modalities and offering hope for improved survival and quality of life in cancer patients.

In summary, epigenetic therapy for cancer represents a sophisticated and promising treatment paradigm that addresses the dynamic and reversible nature of gene regulation in malignancies. While challenges remain, ongoing clinical trials and technological innovations are gradually unraveling the full potential of this approach, marking a significant shift towards more effective and tailored cancer care.

Epigenetic Therapy For Cancer

epigenetic therapy for cancer: Epigenetic Therapy of Cancer Michael Lübbert, Peter A. Jones, 2013-12-12 The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders is now being translated into treatment approaches that target the epigenetic defects pharmacologically. This book first presents the latest evidence regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.

epigenetic therapy for cancer: Epigenetic Cancer Therapy Steven Gray, 2023-05-03 Epigenetic Cancer Therapy, Second Edition provides a comprehensive discussion of healthy and aberrant epigenetic biology, along with new discoveries to improve our understanding of cancer epigenetics and therapeutics. The book encompasses large-scale intergovernmental initiatives, as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Since the publication of the first edition of this book, the field of epigenetics has undergone significant change. New epigenetic therapies have been designed and approved for clinical use. Our knowledge of the plasticity of the epigenome in cancer and disease has expanded dramatically, with increasing evidence linking pollution to epigenetic changes in cancer development. This second edition has been fully updated to address these changes, along with promising therapeutic programs such as CRISPR/Cas9 mediated approaches, CAR-T based therapies, epigenetic priming, histone modifications, and similar, transformative advances across synthetic biology and cellular engineering. - Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies - Covers new findings in the interplay between cancer stem cells (CSCs) and drug resistance, thus demonstrating that epigenetic machinery is a candidate target for the eradication of these CSCs - Provides a fully updated resource on new topics, including the epitranscriptome, oncohistones, single cell analysis, epigenetic priming, CRISPR therapy, CAR-T therapy, and epigenetics and pollution - Features chapter contributions from leading experts in the field

epigenetic therapy for cancer: *Epigenetic Therapy with Histone Deacetylase Inhibitors: Implications for Cancer Treatment* Christiane Pienna Soares, Jean Leandro Dos Santos, Ângela Sousa, 2021-06-02

epigenetic therapy for cancer: Epigenetic therapy against cancer: Toward new molecular targets and technologies Christiane Pienna Soares, Ângela Sousa, Chung Man Chin, Fatima Valdes-Mora, Daniela Trisciuoglio, 2023-06-27

epigenetic therapy for cancer: Epigenetics Territory and Cancer Parvin Mehdipour, 2015-03-18 This book explores epigenetic strategies, bridging fundamental cancer epigenetics, different paradigms in tumor genetics and translational understanding for both the clinic and improved lifestyles. The work provides target-based insights for treating different types of cancers and presents research on evolutionary epigenetics, introducing ‘Medical Epi- Anthropology’ and ‘Cancer Epi-Anthropology’. Translating multi-disciplinary research into therapeutic design is at the core of this book. Readers may explore how cancer management involves unmasking the involved networks and the interactive status of different genes to achieve the appropriate methylome based therapy. Early chapters explore fundamental aspects and brain tumours, whilst later chapters investigate breast cancer and various other cancers, and the final chapter presents an evolutionary

insight in cancer epigenetics, considering that the epigene is beyond DNA methylation, RNA interference and histone modification in cancer development. This book will be of interest to researchers in different medical and scientific fields, including clinical management (diagnosis, prognosis, prediction, prevention, and guidelines), genetic education, nutrition and nutrigenomics, industrial chemistry, and drug innovation. Because of the unique bridging between science and medicine this book will also be useful as an educational and translational research package.

epigenetic therapy for cancer: Epigenetic Mechanisms in Breast Cancer Therapy and Resistance Sanchita Bhatnagar, 2024-11-25 Epigenetic mechanisms are essential for normal mammalian development and maintenance of gene expression patterns. Disruption of epigenetic processes can lead to altered transcriptional regulation, gene levels, and malignant cellular transformation. Global alterations of the epigenetic landscape are a hallmark of tumorigenesis and metastasis. Conventionally, cancer was thought to be a genetic disease, but recent advancement in the field identified an abundance of epigenetic abnormalities along with genetic alterations. The extensive reprogramming of epigenetic machinery in cancer includes DNA methylation, histone modifications, nucleosome positioning and non-coding RNAs, specifically microRNA expression. Additionally, the reversible nature of epigenetic aberrations has led to the emergence of the promising field of epigenetic therapy, and recent FDA approval of epigenetic drugs for cancer treatment. This book focuses on the epigenetic mechanisms in breast cancertherapy and resistance. It is organized into three sections, including epigenetic mechanisms in breast cancer, targeting epigenetic mechanisms for new therapies, and new and emerging methodologies to study epigenetic alterations in breast cancer. Chapters highlight various epigenetic regulations that prevent breast cancer growth and progression, as well as epigenetic alterations that contribute to breast cancer progression. This text is a useful methodology book for researchers and students interested in epigenetics in breast cancer and the fundamentals of cancer biology.

epigenetic therapy for cancer: Epigenetics and Cancer Fazlul H. Sarkar, 2013-05-29 Overall, this book illustrates the complexities of the regulation and deregulation of genes mediated through epigenetics in the development and progression of human malignancies. All the articles have been carefully chosen to represent several cancer systems with state of our knowledge on the role of epigenetic deregulation of microRNAs (miRNAs) and their target mRNAs along with epigenetic deregulation of mRNAs. This book also illustrates the role of several dietary agents, collectively called nutraceuticals or natural agents in modulating the epigenetic reprogramming of miRNAs and mRNAs for the prevention and/or treatment of human malignancies. It is well known that genetic aberrations, especially inherited through parents (somatic genetic alterations) contribute to the development of less than 10% of all cancer yet epigenetic alterations in genes especially through selective methylation and acetylation appears to be responsible for the development and progression of the vast majority of all cancers. Therefore, understanding the role of epigenetics in the regulation of genes especially through deregulated expression of miRNAs as presented in this book will allow scientists to devise targeted therapeutic strategies for re-expression of the lost genes or down-regulate the genes that are over-expressed in order to eradicate cancer. It is hoped that targeting epigenetics will not only target cancer cells but it will also target the tumor microenvironment (more like the entire tumor environment such as the entire host) for achieving better treatment outcomes for patients diagnosed with cancer which will lead to achieve the long-term objective for complete eradication of cancer. This book contains fifteen chapters which begins with the concept of systems and network biology for investigating the epigenetics of cancer followed by a series of articles on the role of miRNAs and their target genes in the biology of pancreatic cancer and other cancers such as breast, kidney, prostate and and colon. Since it is becoming increasingly clear that cancer stem cells (CSCs) are important in the development and progression of cancer, and CSCs are important in therapeutic resistance, treatment failure and tumor recurrence, thus the importance of CSCs and epigenetics has been highlighted by a very timely article on epigenetic variations of stem cell markers in cancer including miRNAs. Moreover, just targeting heterogeneous cancer cell populations may not be optimal to eradicate tumors and for

which one must take a holistic approach for developing drugs that could also target the tumor microenvironment and tumor dormancy that are regulated through epigenetics. Keeping abreast with this thought process the concluding chapter provides a concept towards curative cancer therapy with maspin, which could be a unique window of opportunity to target tumor dormancy. Therefore, it suggest that targeting the tumor dormancy and the tumor microenvironment using novel therapeutics specifically by targeting epigenetics would become the future of medicine.

epigenetic therapy for cancer: Cancer Epigenetics Trygve Tollefsbol, 2008-09-19 During the past few decades, it has become increasingly apparent that heredity is not the sole determining factor in disease development, such as cancer. This landmark work covers a wide array of aspects in the relatively new area of epigenetics, ranging from its role in the basic mechanisms of tumorigenesis, to the newest epigenetic drugs being de

epigenetic therapy for cancer: *Epigenetic Regulation of Cancer-Part C* , 2024-08-23 Epigenetic Regulation of Cancer, Part C, Volume 389 in the International Review of Cell and Molecular Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of hot topics, including Epigenetic biomarkers in breast cancer, Contribution of epigenetics to virus-driven cancer, Cancer metabolism and epigenetics, Technologies for epigenome editing, Epigenetics and cancer stemness, Epigenetic modifications in obesity-associated cancers, Epigenetics in cf microRNA in blood of solid tumors, Integrative analysis of transcriptome, chromatin accessibility, cell surface antigen in single cell level for AML, and more.Additional chapters cover Epigenetics in lung cancer, Gene Regulatory Mechanisms underlying therapy resistance in Cancer, Role of miRNAs as epigenetic regulators of immune checkpoints in cancer immunity, Epigenetic contributions to Acute myeloid leukemia (AML), Contribution of epigenetics to chemoresistance, Epigenetic contribution to the relationship between obesity and cancer, and Epigenetic regulation in ovarian cancer. - Provides the latest information on cancer research - Offers outstanding and original reviews on a range of cancer research topics - Serves as an indispensable reference for researchers and students alike

epigenetic therapy for cancer: *Cancer Epigenetics* Antonio Giordano, Marcella Macaluso, 2011-10-07 Cancer Epigenetics: Biomolecular Therapeutics in Human Cancer is the only resource to focus on biomolecular approaches to cancer therapy. Its presentation of the latest research in cancer biology reflects the interdisciplinary nature of the field and aims to facilitate collaboration between the basic, translational, and clinical sciences.

epigenetic therapy for cancer: Cutting Edge Therapies for Cancer in the 21st Century Pier Paolo Claudio, Paraskevi Vogiatzi, 2014-04-23 Cancer is a broad group of diseases involving unregulated cell growth with elevated death rates as more people live in old age with mass lifestyle changes occurring in the world. The causes of cancer are diverse, complex, and still only partially understood. The chances of surviving the disease vary remarkably by the type and location of the malignancy and the extent of disease at the start of treatment. Early cancer detection is proving to be a valid approach. Cancer can be detected in a number of ways, including the presence of certain signs and symptoms, screening tests, or medical imaging. Cancer therapy is dynamically changing and revision and change in patient management is constant as our knowledge increases. Cancer is routinely treated with chemotherapy, radiation therapy and surgery. Tailored cancer targeted therapy is becoming an emerging objective of today. In this book, a constructive group of cancer research experts bring the reader their shared vision, to give an extensive and realistic view of individual tumors such as breast, oral, prostate, gastric, and neuroendocrine tumors. New and contemporary terms and concepts in genetics and epigenetics, diet, anticancer treatments, and anticancer drug delivery systems are introduced in this volume. This reference highlights present experimental strategies and key findings that enhance our understanding of cancer and of future therapies. This eBook is aimed at a broad audience of undergraduates, medical students, PhDs, cancer researchers, and also cancer patient families with the goal to conceive a curiosity about the subjects presented that will hopefully lead to further studies.

epigenetic therapy for cancer: Epigenetics of Cervical Cancer Shama Prasada Kabekkodu,

Aniruddha Chatterjee, Sanjiban Chakrabarty, 2025-05-12 This book focuses on the fundamentals of epigenetics, covering the roles of DNA methylation, histone modifications, and non-coding RNA, especially miRNA and lncRNA, in cervical cancer. The chapters discuss various methods to detect epigenetic changes and how these changes could be useful for diagnosis, prognosis, as well as epigenetic therapy. Further chapters address the up-to-date approaches and solutions to the parameterizing bottlenecks associated with the translation of these findings for the management of cervical cancer. The book is supplemented with figures and tables to aid conceptual understanding. The book is relevant for researchers, academicians, scientists, as well as medical students seeking to understand the fundamentals of cervical cancer based on environmental or genetic factors.

epigenetic therapy for cancer: Epigenetic Regulation in Overcoming Chemoresistance Chunfu Wu, Lihui Wang, 2021-06-26 Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers. - Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult - Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials - Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

epigenetic therapy for cancer: Epigenetics and Cancer, Part A , 2010-11-22 Genes interact with the environment, experience, and biology of the brain to shape an animal's behavior. This latest volume in Advances in Genetics, organized according to the most widely used model organisms, describes the latest genetic discoveries in relation to neural circuit development and activity. - Explores the latest topics in neural circuits and behavior research in zebrafish, drosophila, C.elegans, and mouse models - Includes methods for testing with ethical, legal, and social implications - Critically analyzes future prospects

epigenetic therapy for cancer: Molecular basis of epigenetic regulation in cancer therapies Ángeles Carlos Reyes, César López-Camarillo, Guillermo Barreto, Heriberto Prado-Garcia, Susana Romero-Garcia, 2023-02-10

epigenetic therapy for cancer: *Drug Discovery in Cancer Epigenetics* Gerda Egger, Paola Arimondo, 2015-11-19 Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. - Highlights the potential of epigenetic alterations in cancer for drug development - Covers the tools and methods for epigenetic drug discovery, preclinical and clinical testing, and clinical implications of epigenetic therapy - Provides important information regarding putative epigenetic targets, epigenetic technologies, networks and consortia for epigenetic drug discovery and routes for translation

epigenetic therapy for cancer: Epigenetics of Cancer Prevention Anupam Bishayee, Deepak Bhatia, 2018-11-27 Epigenetics of Cancer Prevention, Volume Ten is the first to look at epigenetics and chemoprevention together. Although there is numerous scientific data available on how epigenetics can lead to cancer and how chemoprevention can be beneficial in the treatment of, or improvement of quality of life, together they will set an advanced understanding for the reader in this upcoming field of chemoprevention influencing epigenetics. This book discusses molecular epigenetic targets of natural products, such as green tea polyphenols, curcumin and resveratrol, and organ specific epigenetic targets related to diverse types of cancer, for example prostate, colorectal, breast, lung and skin cancers. Additionally, it encompasses a discussion on research methods and limitations to study epigenetics and epigenomics of chemopreventive drugs and personalized cancer treatment with phytochemicals. The book is ideal for cancer researchers, health care professionals and all individuals who are interested in cancer prevention research and its clinical applications, especially in natural remedies. - Lists natural agents, including nutraceuticals, and their effects on normal or tumor genome - Addresses various epigenetic systems and mechanisms in the regulation and support of the mammalian genome - Discusses how various parts of dietary phytochemicals can influence or modify epigenetic mechanisms in several types of cancer

epigenetic therapy for cancer: Personalized Epigenetics Trygve Tollefsbol, 2024-07-17 Personalized Epigenetics, Second Edition discusses the core translatability of epigenetics to health management of individuals who have unique variations in their epigenetic signatures that can guide both disorder and disease prevention and therapy. Fully updated and revised, this new edition details inter-individual variability in the major epigenetic process in humans consisting of DNA methylation, histone modifications, noncoding RNA, and the diagnostic, prognostic, and therapeutic potential of the field. It also reviews the impact of the environment on epigenetic variations among individuals and the role of pharmacology and drug development in personalized epigenetics.Most importantly, the text covers personalized epigenetics from a disease-oriented perspective, presenting chapters that provide advances in widespread disorders or diseases, including diabetes, cancer, autoimmune disorders, obesity, cardiovascular diseases, neurological disorders, and pain management. - Includes new chapters on topics such as the limitations of personalized epigenetic variation comparisons; personalized epigenetics technologies; epigenetics of personalized nanomedicine; personalized epigenetic management of diabetes; epigenetics and chemoresistance; and personalized epigenetics and neurological disorders - Covers key methodological processes that are important in personalized medicine - Offers disease research case studies to provide in-depth discussion of examples of recent epigenetic research on a disease area - Features topics such as forensic epigenetics, epigenetics of personalized toxicity, limitations of epigenetic variation comparisons, and nanomedicine and nutrigenomics as applied to personalized epigenetics

epigenetic therapy for cancer: Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies Alma D. Campos-Parra, Carlos Pérez-Plasencia, Teresita Padilla-Benavides, Eduardo López-Urrutia, 2021-08-26

epigenetic therapy for cancer: *Metabolism and Epigenetic Regulation: Implications in Cancer* Tapas Kumar Kundu, Chandrima Das, 2022-10-27 Metabolic programs of individuals are key determinants for disease susceptibility and immune response. This book, edited by experts in the field, summarizes epigenetic signaling pathways that regulate metabolic programs associated with cancer and cancer-related secondary diseases. The first part of the book highlights key metabolic pathways that are implicated in cancer and provides a comprehensive overview on the carbohydrate, protein, lipid, amino- and nucleic acid metabolic pathways that are deregulated in cancer. Special attention is paid to the altered tumor micro-environment that is influenced by the metabolic milieu. Furthermore, the fundamental relationship between the cellular metabolic environment and cell death-mediated autophagy is discussed. The second part of the book covers our understanding of the fundamental epigenetic regulations that are implicated in controlling the metabolic programs in cancer cells. Many aspects of epigenetic regulation of non-coding RNAs as well as DNA/RNA methylation, which influencing metabolic homeostasis in cancer, are discussed in detail. Special

emphasis is placed on the epigenetic regulation of the amino acid, glucose/carbohydrate metabolism and epigenetic regulation during hypoxia and its connection to cancer. Last but not least, the third part of the book covers small molecule modulators of histone modifying enzymes, which can be used as therapeutic tools. The readers learn about the cross-talk between epigenetics and immunometabolims, as well as the epigenetic regulation of oncometabolites to combat cancer. Given its scope, the book will appeal to a broad readership interested in epigenetic, cancer and metabolic research.

Related to epigenetic therapy for cancer

Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications (Gut10d) Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide, largely due to the limited efficacy of

Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications (Gut10d) Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide, largely due to the limited efficacy of

When cancer cells feel squeezed, they become more dangerous (Science Daily10d) New research shows that cancer cells don’t just grow; they adapt when stressed. When squeezed inside tissues, they transform

When cancer cells feel squeezed, they become more dangerous (Science Daily10d) New research shows that cancer cells don’t just grow; they adapt when stressed. When squeezed inside tissues, they transform

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging (Corpus Christi Caller-Times1mon) In vitro findings reveal Telomir-1’s dual action: targeting DNA methylation switches and cutting into the Wnt “fuel line” that drives cancer growth. MIAMI, FLORIDA / ACCESS Newswire / August 28, 2025

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging (Corpus Christi Caller-Times1mon) In vitro findings reveal Telomir-1’s dual action: targeting DNA methylation switches and cutting into the Wnt “fuel line” that drives cancer growth. MIAMI, FLORIDA / ACCESS Newswire / August 28, 2025

How Physical Stress Pushes Cancer Cells Into Dangerous New States (19d) Pressure from surrounding tissues activates invasive programs in cancer cells. This mechanical stress rewires epigenetic regulation. Cancer cells are notoriously adaptable, capable of shifting their

How Physical Stress Pushes Cancer Cells Into Dangerous New States (19d) Pressure from surrounding tissues activates invasive programs in cancer cells. This mechanical stress rewires epigenetic regulation. Cancer cells are notoriously adaptable, capable of shifting their

Reasons why cancer treatments may stop working: Understanding drug resistance (1don MSN) Cancer treatment resistance, a significant challenge, arises when cancer cells adapt to therapy through genetic mutations,

Reasons why cancer treatments may stop working: Understanding drug resistance (1don MSN) Cancer treatment resistance, a significant challenge, arises when cancer cells adapt to therapy through genetic mutations,

Related Articles

- truth beard winston brothers 1
- executive functioning assessment free
- qatar pharmacist prometric exam

Back to Home